QSI trades 0.1% below Wall Street's consensus target of $1.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes QSI achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 2 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 23, 2026, Quantum-Si incorporated (QSI) has a Wall Street consensus price target of $1.00, based on estimates from 2 covering analysts. With the stock currently trading at $0.92, this represents a potential upside of +0.1%. The company has a market capitalization of $182M.
Analyst price targets range from a low of $1.00 to a high of $1.00, representing a 0% spread in expectations. The median target of $1.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 1 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, QSI trades at a trailing P/E of -1.8x. Analysts expect EPS to grow +9.7% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
PACBPacific Biosciences of California, Inc. | $410M | $1.32 | $1.00 | -28.6% | Buy | — | 18 |
CDNACareDx, Inc | $1.3B | $25.05 | $27.00 | +3.1% | Buy | 28.0x | 13 |
ACMRACM Research, Inc. | $6.8B | $103.17 | $100.00 | -9.0% | Buy | 55.2x | 10 |
ILMNIllumina, Inc. | $24.5B | $161.38 | $151.40 | -6.5% | Buy | 31.0x | 50 |
FLGTFulgent Genetics, Inc. | $531M | $17.84 | $15.00 | -16.7% | Buy | — | 9 |
SEERSeer, Inc. | $97M | $1.76 | $4.00 | +129.9% | Hold | — | 4 |
TMOThermo Fisher Scientific Inc. | $172.4B | $464.01 | $599.70 | +29.1% | Buy | 18.7x | 42 |
DHRDanaher Corporation | $126.1B | $178.23 | $230.89 | +30.3% | Buy | 21.0x | 43 |
AAgilent Technologies, Inc. | $35.7B | $126.49 | $154.75 | +21.8% | Buy | 21.0x | 41 |
BIOBio-Rad Laboratories, Inc. | $7.6B | $280.96 | $321.67 | +13.9% | Buy | 31.2x | 14 |
Quick answers to the most common questions about buying QSI stock.
The consensus price target for QSI is $1, close to the current price of $0.9212 (0.1% implied move). Based on 2 analyst estimates, the stock appears fairly valued near current levels.
QSI has a consensus rating of "Buy" based on 2 Wall Street analysts. The rating breakdown is mixed, with 1 Hold ratings making up the largest segment. The consensus 12-month price target of $1 implies 0.1% upside from current levels.
QSI's current price is $0.9212 with a consensus target of $1 (0.1% implied move). Analyst estimates suggest the stock is fairly valued at current levels.
The most bullish Wall Street analyst has a price target of $1 for QSI, while the most conservative target is $1. The consensus of $1 represents the median expectation. These targets typically reflect 12-month expectations.
QSI is lightly followed, with 2 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 1 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month QSI stock forecast based on 2 Wall Street analysts shows a consensus price target of $1, with estimates ranging from $1 (bear case) to $1 (bull case). The median consensus rating is "Buy".
QSI appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $1 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
QSI analyst price targets range from $1 to $1, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $1 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.